Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition).
10.3760/cma.j.cn112152-20200410-00330
- VernacularTitle:聚乙二醇化脂质体多柔比星不良反应管理中国专家共识(2020版)
- Collective Name:Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
- Publication Type:Journal Article
- Keywords:
Adverse event;
Expert consensus;
Hand-foot syndrome;
Infusion reaction;
Management;
Oral mucositis;
Pegylated liposomal doxorubicin
- MeSH:
Antibiotics, Antineoplastic;
adverse effects;
therapeutic use;
Consensus;
Doxorubicin;
adverse effects;
analogs & derivatives;
therapeutic use;
Drug-Related Side Effects and Adverse Reactions;
prevention & control;
Female;
Hand-Foot Syndrome;
complications;
Humans;
Neoplasms;
drug therapy;
Polyethylene Glycols;
adverse effects;
therapeutic use;
Practice Guidelines as Topic;
Stomatitis;
complications
- From:
Chinese Journal of Oncology
2020;42(8):617-623
- CountryChina
- Language:Chinese
-
Abstract:
As a new type of anthracyclines, pegylated liposomal doxorubicin (PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer, breast cancer, multiple myeloma, and so on. Compared with traditional anthracyclines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will be accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order to improve the therapeutic efficacy of PLD and life quality of patients.
